22 Although the diplopia responder rate was not significantly different between the groups, diplopia was completely resolved in 50% of patients in the teprotumumab group, versus 20% in the placebo group (nominally significant difference).
← all excerpts
A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.
1
—
—